Literature DB >> 2231917

Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer.

W H Rawls1, D L Lamm, B A Lowe, E D Crawford, M F Sarosdy, J E Montie, H B Grossman, P T Scardino.   

Abstract

Intravesical administration of bacillus Calmette-Guerin has been shown to be highly effective treatment of superficial bladder cancer. Complications from bacillus Calmette-Guerin therapy are usually minor but serious and even fatal reactions can occur. Five recent cases illustrate the gravity of bacillus Calmette-Guerin sepsis. One man with severe debility and the organic brain syndrome died acutely with a fever of 40 C. Two men had frank sepsis that progressed to multiorgan failure and death. Sepsis progressed despite the use of isoniazid, rifampin and streptomycin. Two men who had equally progressive sepsis with intravesical bacillus Calmette-Guerin survived with the use of cycloserine for the first 72 hours of treatment. Triple antituberculous antibiotics, including cycloserine, may be lifesaving. Sepsis resulted from intravenous absorption through inflamed or disrupted urothelium. Bacillus Calmette-Guerin treatment should not be administered in the presence of severe cystitis or after grossly traumatic catheterization.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2231917     DOI: 10.1016/s0022-5347(17)39731-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  17 in total

1.  Rapid identification of mycobacteria and drug-resistant Mycobacterium tuberculosis by use of a single multiplex PCR and DNA sequencing.

Authors:  Ailyn C Pérez-Osorio; David S Boyle; Zachary K Ingham; Alla Ostash; Romesh K Gautom; Craig Colombel; Yolanda Houze; Brandon T Leader
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

Review 2.  Bladder cancer in the elderly.

Authors:  Shahrokh F Shariat; Matthew Milowsky; Michael J Droller
Journal:  Urol Oncol       Date:  2009 Nov-Dec       Impact factor: 3.498

3.  Evaluation of a low-dose intravesical bacillus Calmette-Guérin (Tokyo strain) therapy for superficial bladder cancer.

Authors:  M Takashi; K Wakai; Y Ohno; T Murase; K Miyake
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

4.  Pulmonary tuberculosis due to bacille Calmette-Guérin.

Authors:  D Kirsten; U Rieger; K H Schröder; A Böhle; H Magnussen
Journal:  Clin Investig       Date:  1993-10

Review 5.  Medical management of patients with refractory carcinoma in situ of the bladder.

Authors:  J C Kim; G D Steinberg
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

6.  Acute renal failure due to interstitial nephritis after intravesical instillation of BCG.

Authors:  Maria Jose Manzanera Escribano; Enrique Morales Ruiz; Mónica Odriozola Grijalba; Eduardo Gutierrez Martínez; Alfredo Rodriguez Antolín; Manuel Praga Terente
Journal:  Clin Exp Nephrol       Date:  2007-09-28       Impact factor: 2.801

Review 7.  BCG in the treatment of superficial cancer of the bladder: a review.

Authors:  S Friberg
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

8.  Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response.

Authors:  I Fukui; K Kihara; H Sekine; Y Tachibana; T Kawai; D Ishiwata; H Oshima
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 9.  Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.

Authors:  Yuan-qiang Zheng; Youssef W Naguib; Yixuan Dong; Yan-chun Shi; Shorgan Bou; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2015       Impact factor: 5.217

Review 10.  Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder.

Authors:  Timothy P Kresowik; Thomas S Griffith
Journal:  Immunotherapy       Date:  2009-03       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.